Primary and Metastatic Brain Tumors

  • J. L. Villano
  • E. E. Vokes


The Central Brain Tumor Registry of the United States estimates 11.3 cases per 100,000 person years for all primary benign and malignant brain tumors, with malignant brain tumors comprising half of the cases [1]. Similarly, the American Cancer Society estimates 17,000 new cases of primary CNS tumors per year [2]. Incidence rates for primary CNS tumors have a bimodal distribution by age with an early peak between 0 and 4 years of age (3.1 cases per 100,000), followed by a trough between 15 and 24 years of age (1.8 cases per 100,000). The incidence increases later in life and reaches a plateau after 65 years of age (19 cases per 100,000) [3]. Metastatic brain disease is more common than primary brain tumors, occurring in 15%-30% of all cancers (approximately 135,000 patients per year), and contributing to 13% of all cancer related deaths [3].


Brain Tumor Clin Oncol Radiat Oncol Biol Phys Anaplastic Astrocytoma Primary Brain Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Central brain tumor registry of the United States (2000) Statistical report: primary brain tumors in the United States, 1992–1997. CBTRUS, ChicagoGoogle Scholar
  2. 2.
    American Cancer Society (2001) Cancer facts and figures-2001. ACS, AtlantaGoogle Scholar
  3. 3.
    Davis FG, Preston-Martin S (1999) Epidemiology. Incidence and survival. In: Bigner DD, McLendon RE, Bruner JM (eds) Russell and Rubenstein’s pathology of tumors of the nervous system. Oxford University Press, London, pp 7–36Google Scholar
  4. 4.
    Bahemuke M (1988) Worldwide incidence of primary nervous system neoplasms: geographical, racial and sex differences, 1960–1977. Brain 111:737–755CrossRefGoogle Scholar
  5. 5.
    Jukich PJ, McCarthy BJ, Surawicz TS (2001) Trends in incidence of primary brain tumors in the United States, 1985–1994. Neuroonocology 3:141–151Google Scholar
  6. 6.
    DeAngelis LM (2001) Brain tumors. N Engl J Med 344: 114–123PubMedCrossRefGoogle Scholar
  7. 7.
    Preston-Martin S, Mack WJ (1996) Neoplasms of the nervous system. In: Schottenfeld D, Fraumeni JF (eds) Cancer epidemiology and prevention, 2nd edn. Oxford University Press, New York, pp 1231–1281Google Scholar
  8. 8.
    Kleihues P, Cavence WK (eds) (2000) Classification of tumours, pathology and genetics of tumours of the nervous system (World Health Organization). IARC Press, LyonGoogle Scholar
  9. 9.
    Walker AE, Robins M, Weinfeld FD (1985) Epidemiology of brain tumors: the National Survey of Intracranial Neoplasms. Neurology 24:981–985Google Scholar
  10. 10.
    Vanucci RC, Baten M (1974) Cerebral metastatic disease in childhood. Neurology 24:981–985CrossRefGoogle Scholar
  11. 11.
    Delattre JY, Krol G, Thaler HT, Posner JB (1988) Distribution of brain metastases. Arch Neurol 45:741–744PubMedCrossRefGoogle Scholar
  12. 12.
    Posner JB (1995) Pathophysiology of metastasis to the nervous system. In: Posner JB (ed) Neurologic complications of cancer. Davis, Philadelphia, pp 15–22Google Scholar
  13. 13.
    Forsych PA, Posner JB (1993) Headaches in patients with brain tumors: a study of 111 patients. Neurology 43:1678–1683CrossRefGoogle Scholar
  14. 14.
    Van Oostenbrugge RJ, Twijnstra A (1999) Presenting features and value of diagnostic procedures in leptomeningeal metastases. Neurology 53:382–385PubMedCrossRefGoogle Scholar
  15. 15.
    Freilich RJ, DeAngelis LM (1995) Primary central nervous system lymphoma. Neurol Clin North Am 13:901–914Google Scholar
  16. 16.
    Ewend MG, Carey LA, Morris DE et al (2001) Brain metastases. Curr Treat Opt Oncol 2:537–547CrossRefGoogle Scholar
  17. 17.
    Patchell RA, Tibbs PA, Walsh JW et al (1990) A randomized trial of surgery in single metastases to the brain. N Engl J Med 322:494–500PubMedCrossRefGoogle Scholar
  18. 18.
    Bauman G, Lote K, Larson D et al (1999) Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys 45:923–929PubMedCrossRefGoogle Scholar
  19. 19.
    Recht LD, Lew R, Smith TW et al (2000) Suspected low-grade glioma: is deferring treatment safe? Ann Neurol 31:431–436CrossRefGoogle Scholar
  20. 20.
    Karim ABMF, Maat B, Hatlevoll R et al (1996) A randomized trial of dose-response in radiation therapy of low-grade cerebral glioma: European organization for research and treatment of cancer (EORTC) study 22844. Int J Radiat Oncol Biol Phys 36: 549–556PubMedCrossRefGoogle Scholar
  21. 21.
    Shaw E, Arusell R, Scheithauer B et al (1998) A prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a NCCTG-RTOG-ECOG study (abstract). Prog Proc Am Soc Clin Oncol 17:401AGoogle Scholar
  22. 22.
    Karim ABMF, Cornu P, Bleehen N et al (1998) Immediate postoperative radiotherapy in low-grade glioma improves progression free survival, but not overall survival: preliminary results of an EORTC/MRC randomized phase III study (abstract). Prog Proc Am Soc Clin Oncol 17:400AGoogle Scholar
  23. 23.
    Walker MD, Alexander E Jr, Hunt WE et al (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 49:333–343PubMedCrossRefGoogle Scholar
  24. 24.
    Kristiansen K, Hagen S, Kollevold T et al (1981) Combined modality therapy of operated astrocytomas grade III and IV: confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicentre trial of the Scandinavian Glioblastoma Study Group. Cancer 47:649–652PubMedCrossRefGoogle Scholar
  25. 25.
    Shrieve DC, Alexander E 3rd, Black PM et al (1999) Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radio-surgical boost: prognostic factors and long-term outcome. J Neurosurg 90:72–77PubMedCrossRefGoogle Scholar
  26. 26.
    Fine HA, Dear KB, Loeffler JS et al (1992) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71:2585–2597CrossRefGoogle Scholar
  27. 27.
    Medical Research Council Brain Tumor Working Party (2001) Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a medical research council trial. J Clin Oncol 19: 509–518Google Scholar
  28. 28.
    Brandes AA, Palmisano V, Pasetto LM et al (2001) High-dose chemotherapy with bone marrow rescue for high-grade gliomas in adults. Cancer Invest 19:41–48PubMedCrossRefGoogle Scholar
  29. 29.
    Yung WK, Prados MD, Yaya-Tur R et al (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse: Temodal Brain Tumor Group. J Clin Oncol 17:2762–2771PubMedGoogle Scholar
  30. 30.
    Osoba D, Brada M, Yung WK et al (2000) Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol 18:1481–1491PubMedGoogle Scholar
  31. 31.
    Jaeckle KA, Yung WK, Prados MD et al (2000) NABTC 98-03: phase II evaluation of temozolomide and 13-cis retinoic acid for treatment of recurrent and progressive malignant glioma (abstract). Annual meeting of the Society for Neurooncology, Chicago, IL, 9–12 Nov 2000. Neurooncology 2:271Google Scholar
  32. 32.
    Brem H, Piantadosi S, Burger PC et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345:1008–1012PubMedCrossRefGoogle Scholar
  33. 33.
    Esteller M, Garcia-Foncillas J, Andion E et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343: 1350–1354PubMedCrossRefGoogle Scholar
  34. 34.
    Burns KL, Ueki K, Jhung SL et al (1998) Molecular genetic correlates of pl6, cdk4 and pRb immunohistochemistry in glioblastomas. J Neuropathol Exp Neurol 57:122–130PubMedCrossRefGoogle Scholar
  35. 35.
    Watanabe K, Tachibana O, Sata K et al (1996) Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6: 217–223PubMedCrossRefGoogle Scholar
  36. 36.
    Li J, Yen C, Liaw D et al (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943–1947PubMedCrossRefGoogle Scholar
  37. 37.
    Hermanson M, Funa K, Koopmann J et al (1996) Association of loss of heterozygosity on chromosome 17p with high platelet derived growth factor a receptor expression in human malignant gliomas. Cancer Res 56:164–171PubMedGoogle Scholar
  38. 38.
    Cairncross JG, Macdonald DR (1988) Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23:360–364PubMedCrossRefGoogle Scholar
  39. 39.
    Fortin D, Cairncross GJ, Hammond RR (1999) Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery 45:1279–1291PubMedCrossRefGoogle Scholar
  40. 40.
    Smith JS, Perry A, Borell TJ et al (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636–645PubMedGoogle Scholar
  41. 41.
    Schabet M (1999) Epidemiology of primary CNS lymphoma. J Neurooncology 43:219–226CrossRefGoogle Scholar
  42. 42.
    Morgello S (1995) Pathogenesis and classification of primary central nervous system lymphoma: an update. Brain Pathol 5:383–393PubMedCrossRefGoogle Scholar
  43. 43.
    Nelson DF, Martz KL, Bonner H et al (1992) Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 23:9–17PubMedCrossRefGoogle Scholar
  44. 44.
    Freilich RJ, Delattre JY, Monjour A, DeAngelis LM (1996) Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 46:435–439PubMedCrossRefGoogle Scholar
  45. 45.
    O’Neill BP, O’Fallon JR, Earle JD et al (1995) Primary central nervous system non-Hodgkin’s lymphoma: survival advantages with combined initial therapy? Int J Radiat Oncol Biol Phys 33:663–673PubMedCrossRefGoogle Scholar
  46. 46.
    Abrey LE, Yahalom J, De Angelis LM (2000) Treatment for primary CNS lymphoma: the next step. J Clin Oncol 18: 3144–3150PubMedGoogle Scholar
  47. 47.
    Doolittle ND, Miner ME, Hall WA et al (2000) Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the bloodbrain barrier for the treatment of patients with malignant brain tumors. Cancer 88:637–647PubMedCrossRefGoogle Scholar
  48. 48.
    Soussain C, Suzan F, Hoang-Xuan K et al (2001) Results of intensive chemotherapy followed by hematopoietic stemcell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 19:742–749PubMedGoogle Scholar
  49. 49.
    Chamberlain MC (2001) Meningiomas. Curr Treat Opt Neurol 3:67–75CrossRefGoogle Scholar
  50. 50.
    Kondziolka D, Levy El, Niranjan A et al (1999) Long-term outcomes after meningioma radiosurgery: physician and patient perspectives. J Neurosurg 91:44–50PubMedCrossRefGoogle Scholar
  51. 51.
    Grunberg SM, Weiss MH, Spitz IM et al (1991) Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 74:861–866PubMedCrossRefGoogle Scholar
  52. 52.
    Newton HB, Slivka MA, Stevens C et al (2000) Hydroxyurea chemotherapy for unresectable or residual meningioma. J Neurooncol 49:165–170PubMedCrossRefGoogle Scholar
  53. 53.
    Cerda-Nicolas M, Lopez-Gine SC, Perez-Bacete M et al (2000) Histopathological and cytogenetic findings in benign, atypical and anaplastic human meningiomas: a study of 60 tumors. J Neurooncol 47:99–108PubMedCrossRefGoogle Scholar
  54. 54.
    Flickinger JC, Kondziolka D, Lunsford LD et al (1994) A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasis. Int J Radiat Oncol Biol Phys 28:797–802PubMedCrossRefGoogle Scholar
  55. 55.
    Breneman JC, Warnick R, Albright RE Jr et al (1997) Stereotactic radiosurgery for the treatment of brain metastases: results of a single institution series. Cancer 79: 551–557PubMedCrossRefGoogle Scholar
  56. 56.
    Schaberg J, Gainor BJ (1985) A profile of metastatic carcinoma of the spine. Spine 10:19–20PubMedCrossRefGoogle Scholar
  57. 57.
    Bryne TN (1992) Spinal cord compression from epidural metastases. N Engl J Med 327:614–619CrossRefGoogle Scholar
  58. 58.
    Maranzano E, Latini P (1995) Effectiveness of radiation therapy without surgery in metastatic spinal cord compression: final results from a prospective trial. Int J Radiat Oncol Biol Phys 32:959–967PubMedCrossRefGoogle Scholar
  59. 59.
    DeAngelis LM (1998) Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol 38:245–252PubMedCrossRefGoogle Scholar
  60. 60.
    Balm M, Hammack J (1996) Leptomeningeal carcinomatosis: presenting features and prognostic factors. Arch Neurol 53:626–632PubMedCrossRefGoogle Scholar
  61. 61.
    Glantz MJ, Jaeckle KA, Chamberlain MC et al (1999) A randomized controlled trial comparing intrathecal sustainedrelease Cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5:3394–3402PubMedGoogle Scholar
  62. 62.
    Grossman SA, Finkelstein DM, Ruckdeschel JC et al (1993) Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol 11:561–569PubMedGoogle Scholar
  63. 63.
    Bokstein F, Lossos A, Siegal T et al (1998) Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer 82:1756–1763PubMedCrossRefGoogle Scholar
  64. 64.
    Glantz MJ, Cole BF, Recht L et al (1998) High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol 16:1561–1567PubMedGoogle Scholar
  65. 65.
    Friedman HS, Kokkinakis DM, Pluda J et al (1998) Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol 16:3570–3575PubMedGoogle Scholar
  66. 66.
    Schinkel AH (1998) Pharmacological insights from p-glycoprotein knockout mice. Int J Clin Pharm Ther 36:9–13Google Scholar
  67. 67.
    Kilic T, Alberta JA, Zdunek PR et al (2000) Intracranial inhi bition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Can Res 60:5143–5150Google Scholar
  68. 68.
    Kleinberg L, Grossman SA, Piantadosi S et al (1999) Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR 13, a novel radioenhancer in newly diagnosed glioblastoma multiforme. J Clin Oncol 17:2593–2603PubMedGoogle Scholar
  69. 69.
    Stupp R, Dietrich PY, Ostermann Kraljevic S et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J of Clin Oncol 20:1375–1382CrossRefGoogle Scholar
  70. 70.
    Ram Z, Culver KW, Oshiro EM et al (1997) Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 3:1354–1361PubMedCrossRefGoogle Scholar
  71. 71.
    BenedettiS, Pirola B, Pollo B et al (2000) Gene therapy of experimental brain tumors using neural progenitor cells. Nat Med 6:447–450CrossRefGoogle Scholar
  72. 72.
    Puduvalli VK, Sawaya R (2000) Antiangiogenesis-therapeutic strategies and clinical implications for brain tumors. J Neurooncol 50:189–200PubMedCrossRefGoogle Scholar
  73. 73.
    Takano T, Lin JH, Arcuino G et al (2001) Glutamate release promotes growth of malignant gliomas. Nature Med 7:1010–1015PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • J. L. Villano
  • E. E. Vokes

There are no affiliations available

Personalised recommendations